Xeris Insider Notice: 107,500 NASDAQ Shares Via Morgan Stanley

Rhea-AI Filing Summary

Xeris Biopharma (XERS) submitted a Form 144 notice proposing the sale of 107,500 shares of common stock, with an aggregate market value of $786,451.77, to be offered through Morgan Stanley Smith Barney LLC on NASDAQ with an approximate sale date of 08/13/2025. The filing lists 161,480,367 shares outstanding and discloses three restricted-stock acquisition lots: 15,000 shares on 06/07/2023, 42,500 on 06/05/2024, and 50,000 on 06/04/2025. No securities of the issuer were reported sold in the past three months. The notice includes the standard certification that the seller does not possess undisclosed material information and references Rule 10b5-1 trading plans.

Insights

Securities Analyst

TL;DR: Routine Form 144 notice for a sub-1% proposed sale; no past three-month sales reported.

The filing documents a proposed sale of 107,500 common shares valued at $786,451.77 to be executed via Morgan Stanley on NASDAQ on or about 08/13/2025. The filing identifies three restricted-stock grants as the source of the shares, with acquisition dates in 2023, 2024 and 2025. The filer reports Nothing to Report for sales in the prior three months and includes the standard representation about absence of undisclosed material information. Based on the disclosed numbers, this appears to be a routine Form 144 notification rather than a material market-moving event.

Corporate Governance Expert

TL;DR: Disclosure is consistent with Rule 144 mechanics; key seller identity is not provided in the visible fields.

The notice specifies the broker, the class of security, quantities, aggregate market value and acquisition details for restricted stock lots but does not provide a named seller in the visible content. The filing reiterates the signatory's certification about lacking material nonpublic information and mentions trading-plan provisions. For governance review, the document supplies transaction-level detail required by Rule 144 but omits explicit filer identifier details in the provided text, which limits assessment of insider status or related party implications.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	107500	786451.77	161480367	08/13/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/07/2023	Restricted Stock	Issuer			15000	06/07/2023	Not Applicable
Common	06/04/2025	Restricted Stock	Issuer			50000	06/04/2025	Not Applicable
Common	06/05/2024	Restricted Stock	Issuer			42500	06/05/2024	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many XERS shares are proposed for sale in this Form 144?

The notice proposes the sale of 107,500 shares of common stock with an aggregate market value of $786,451.77.

When and where is the proposed sale expected to occur for XERS shares?

The approximate date of sale is listed as 08/13/2025 and the securities are to be sold on NASDAQ through Morgan Stanley Smith Barney LLC.

What acquisition details does the Form 144 provide for the XERS shares to be sold?

The filing shows three restricted-stock acquisitions: 15,000 shares on 06/07/2023, 42,500 shares on 06/05/2024, and 50,000 shares on 06/04/2025.

Were any XERS securities sold by the seller in the past three months according to the filing?

The filing reports Nothing to Report for securities sold during the past three months.

Does the Form 144 indicate whether the seller has undisclosed material information?

The notice includes the signer's representation that they do not know any material adverse information about the issuer that has not been publicly disclosed.

Who is the named seller of the XERS shares in this Form 144?

The provided content does not specify the name of the person for whose account the securities are to be sold.